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underlying etiology. Differences in clinical features and outcomes among patients with nonhistaminergic versus histaminergic angioedema in the ED are not well known. We describe the presentations of and identify clinical characteristics associated with patients diagnosed with nonhistaminergic and histaminergic angioedema in the ED.
Methods: We conducted an observational cohort study of consecutive adult patients (age 18 years) evaluated for angioedema in our ED from January 2005 to December 2014. Data were abstracted from the electronic health record with a standardized chart review process. We adhered to the STROBE guidelines for methodological reporting and collected data on demographics, clinical presentation, history, and suspected etiology by ED provider and allergist-immunologist (when available). Univariable associations of select clinical features with etiology were evaluated and utilized to develop a multivariable logistic regression model of these populations and summarized with odds ratios (ORs) and 95% confidence intervals (CIs).
Results: Among 450 consecutive adult angioedema patients, the mean (SD) age was 57 (18) Conclusions: Among ED angioedema patients, those with nonhistaminergic angioedema were more likely to be older, to present beyond 1 hour after symptom onset, to be taking ACE or ARB medications, and less likely to have periorbital or lip edema, urticaria, and dyspnea. Identification of clinical characteristics associated with the underlying etiology of angioedema may assist emergency providers in more rapidly initiating effective therapeutic interventions.
Physiological Effects of a Spit Sock
Vilke G, Lutz M, Sloane C, Castillo E, Brennan J, Swift S, Coyne C/UCSD Medical Center, San Diego, CA; UCSD Medical Center, San Diego, CA Study Objectives: Health care providers and law enforcement utilize spit socks to provide a direct method of universal precautions to prevent exposure to communicable diseases transmitted by bodily fluid projection from an agitated or altered individual. There have been cases in which death of an individual is opined in part to have occurred from limited or reduced ventilation caused by the use of a spit sock. There are no published peer reviewed studies on the use and safety of spit socks in the medical literature. The aim of this study was to evaluate whether there is a clinically significant impact on breathing and ventilation in subjects with a protective spit sock placed on their head.
Methods: This prospective study evaluated the effect of spit sock application on vital signs and ventilatory parameters of healthy adult volunteers, compared to baseline parameters measured without the spit sock. The subjects were placed on a chair and baseline vital signs and ventilatory parameters were taken, including pulse rate, oxygen saturation, blood pressure, respiratory rate, and end-tidal CO 2 . The subjects then sat with the spit mask for 15 minutes and their vital signs and ventilatory parameters were recorded after 5min, 10min and 15min of wearing the mask. Vital signs and ventilatory parameters at 5, 10 and 15 minutes after wearing the spit sock were compared to baseline using students t-test with 95% confidence intervals.
Results: A total of 15 subjects completed the study. The median age was 28 years and 53% were male. There was no significant difference between baseline measurements and measurements obtained while wearing the spit sock for 5, 10 or 15 minutes for pulse rate (p¼0.250, p¼0.181, p¼0.546 respectively), oxygen saturation (p ¼0.334, p¼1.00, p¼0.173 respectively), end-tidal pCO 2 (p¼0.135, p¼0.384, p¼0.187 respectively), and diastolic blood pressure (p¼0.485, p¼0.508, p¼0.915 respectively). For respiratory rate, the difference between baseline rate and rate after spit sock application was not significant after 5 and 10 minutes (p¼0.898 and p¼0.583, respectively), but had statistically significantly decrease at 15 minutes (p¼0.048). The systolic blood pressure was significantly lower after 5 and 10 minutes of spit sock application (p¼0.028 and p¼0.045, respectively), but not significantly different at 15 minutes (p¼0.146). No subject had an increase in ETCO2 above 45 or an O2 sat below 94% at any point during the study. No subject indicated any distress nor did the study need to be terminated early due to pre-determined concerning vital signs or ventilatory parameters.
Conclusions: In healthy subjects there were no clinically significant changes in physiologic parameters of ventilation while wearing a spit sock. This study offers a foundation for further research into the use and safety of spit socks. Study Objectives: Hereditary angioedema (HAE) due to C1-esterase inhibitor (C1-INH) deficiency is characterized by recurrent, debilitating attacks of edema commonly affecting the tongue, larynx, face, trunk, limbs, and abdomen. Laryngeal attacks lead to airway edema and can cause asphyxiation. HAE attacks are also sometimes characterized by intense pain. As a result, HAE attacks can result in visits to emergency departments (ED). HAE medications are available for use in the ED and can reduce the severity and duration of attacks. However, a substantial portion of HAE patients exclusively treat acute attacks with on-demand medications at home, and many use routine prophylaxis. The COMPACT trial was a phase III, randomized, double-blind, placebo-controlled, crossover trial that evaluated the use of subcutaneous C1-INH as routine prophylaxis to prevent HAE attacks and permitted the use of on-demand rescue medication (at home or in hospital settings) at any time during the study. We examined patterns of ondemand rescue medication use during the placebo period of the COMPACT trial (treatment with only on-demand therapies) and explored possible implications for the treatment of HAE in the ED.
Methods: Patients age 12 years with 4 attacks over 2 consecutive months within 3 months of screening were eligible for inclusion in the COMPACT trial and were randomized to a sequence of placebo and active treatment, each for 16 weeks. Patients could use any of the following medications on demand as acute treatment for attacks at any time during the trial: intravenous (IV) plasmaderived (pd) C1-INH (Berinert, CSL Behring, provided by the trial sponsor), ecallantide, icatibant, other IV C1-INH therapy, or fresh frozen plasma. The placebo period of the trial, during which treatment consisted of only on-demand therapy, is the focus of this analysis. The primary endpoint in the COMPACT trial was the time-normalized number of HAE attacks. Use of rescue medication was a key secondary endpoint and severity of attacks was an exploratory endpoint.
Results: A total of 90 patients were randomized to treatment (mean age, 39.6 years; 67% female). During the placebo period of the trial (ie, only on-demand treatment, 4 of 86 patients (4.7%) were attack-free and 3 patients (3.5%) had no treated attacks. During the placebo period, 975 angioedema attacks occurred, including 437 abdominal and 40 laryngeal attacks. Of the 975 attacks, 779 (79.9%) were treated on demand, 97% of them with IV pdC1-INH or icatibant. Of these treated attacks, 179 (23.0%) were mild, 370 (47.5%) were moderate, and 230 (29.5%) were severe. Redosing of medication was required in 23.9% of attacks (38/159) treated with icatibant and 4.2% of attacks (27/636) treated with IV pdC1-INH.
Conclusions: During the placebo period of the COMPACT trial, with use of only on-demand treatment, the attack burden was significant. Abdominal and laryngeal attacks together made up nearly half of the attacks that occurred. An exploratory finding during the placebo period of the trial was that attacks treated with IV pdC1-INH were less likely to require re-dosing than those treated with icatibant, a bradykinin B2 receptor antagonist. This finding may have implications for the on-demand treatment of acute attacks in HAE patients.
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